Difference between revisions of "Brenner tumour"

From Libre Pathology
Jump to navigation Jump to search
 
(5 intermediate revisions by the same user not shown)
Line 7: Line 7:
| Micro      = nests cells that have a "[[coffee bean nucleus]]" (nucleus = elliptical shape, nuclear groove along long axis), distinct nucleoli, moderate-to-abundant gray/pale cytoplasm, dense fibrous stroma around nests
| Micro      = nests cells that have a "[[coffee bean nucleus]]" (nucleus = elliptical shape, nuclear groove along long axis), distinct nucleoli, moderate-to-abundant gray/pale cytoplasm, dense fibrous stroma around nests
| Subtypes  = benign (most common), borderline, malignant
| Subtypes  = benign (most common), borderline, malignant
| LMDDx      = [[granulosa cell tumour]], [[ovarian fibroma]], [[thecoma]]
| LMDDx      = [[granulosa cell tumour]], [[ovarian fibroma]], [[thecoma]], [[Walthard cell rest]]
| Stains    =
| Stains    =
| IHC        = AR +ve, calretinin -ve
| IHC        = AR +ve, calretinin -ve
Line 66: Line 66:
*Main DDx of Coffee bean nucleus = [[granulosa cell tumour]].
*Main DDx of Coffee bean nucleus = [[granulosa cell tumour]].
*Stromal component may be predominant.
*Stromal component may be predominant.
Subclassification:
*Benign.
*Borderline.
*Malignant <5% of tumour.<ref>{{cite journal |authors=Zhang Y, Staley SA, Tucker K, Clark LH |title=Malignant Brenner tumor of the ovary: Case series and review of treatment strategies |journal=Gynecol Oncol Rep |volume=28 |issue= |pages=29–32 |date=May 2019 |pmid=30815527 |pmc=6378317 |doi=10.1016/j.gore.2019.02.003 |url=}}</ref>


DDx:<ref name=Ref_GP437>{{Ref GP|437}}</ref>
DDx:<ref name=Ref_GP437>{{Ref GP|437}}</ref>
Line 80: Line 85:
**Serous carcinoma.
**Serous carcinoma.
**Metastatic urothelial carcinoma.
**Metastatic urothelial carcinoma.
*[[Walthard cell rest]] - typically one nest of cells, lacks the surrounding fibromatous stroma.


===Images===
===Images===
Line 89: Line 95:


==IHC==
==IHC==
Features:<ref>{{Cite journal  | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref>
Features:<ref name=pmid24012099>{{Cite journal  | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref>
*AR +ve.
*[[Androgen receptor|AR]] +ve.
*Calretinin -ve.
*Calretinin -ve.
**Surrounding stroma +ve.
**Surrounding stroma +ve.
*Inhibin +ve.<ref name=pmid24012099>{{cite journal |author=Kuhn E, Ayhan A, Shih IeM, Seidman JD, Kurman RJ |title=Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium |journal=Eur. J. Cancer |volume=49 |issue=18 |pages=3839–49 |year=2013 |month=December |pmid=24012099 |doi=10.1016/j.ejca.2013.08.011 |url=}}</ref>
*Inhibin +ve.<ref name=pmid24012099>{{Cite journal | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref>


==See also==
==See also==

Latest revision as of 18:21, 31 October 2024

Brenner tumour
Diagnosis in short

Brenner tumour. H&E stain.

LM nests cells that have a "coffee bean nucleus" (nucleus = elliptical shape, nuclear groove along long axis), distinct nucleoli, moderate-to-abundant gray/pale cytoplasm, dense fibrous stroma around nests
Subtypes benign (most common), borderline, malignant
LM DDx granulosa cell tumour, ovarian fibroma, thecoma, Walthard cell rest
IHC AR +ve, calretinin -ve
Gross classically solid (may be cystic), usu. well-circumscribed, light yellow colour
Site ovary (see ovarian tumours), fallopian tube

Prevalence uncommon
Prognosis usu. good, may be poor

The Brenner tumour, abbreviated BT, is an ovarian tumour in the epithelial group of ovarian tumours.

General

Epidemiology

  • Mostly benign clinical course - 99% of Brenner tumours benign.[6]
  • Thought to arise from Walthard cell rest.
  • Frequently an incidental finding, i.e. oophorectomy was done for another reason.
  • May be malignant - rarely (~1% of Brenner tumours[7]).

Gross

Features:[8]

  • Classically solid, well-circumscribed, light yellow.
  • May be cystic.

Note:

  • Borderline tumours classically solid and cystic with papillary projections into the cystic component.[8]

Microscopic

Features:

  • Nests of transitional epithelium with cells that have:[9]
    • A "coffee bean nucleus".
      • Elliptical shape (nucleus).
      • Nuclear grooves.
      • Distinct nucleoli.
    • Moderate-to-abundant gray/pale cytoplasm.
  • Dense fibrous stroma around nests.

Notes:

Subclassification:

  • Benign.
  • Borderline.
  • Malignant <5% of tumour.[10]

DDx:[6]

  • Benign:
  • Borderline:
    • Benign Brenner tumour.
    • Malignant Brenner tumour.
    • Metastatic papillary urothelial carcinoma.
  • Malignant:
    • Undifferentiated carcinoma - no Brenner tumour component.
    • Granulosa cell tumour.
    • Serous carcinoma.
    • Metastatic urothelial carcinoma.
  • Walthard cell rest - typically one nest of cells, lacks the surrounding fibromatous stroma.

Images

IHC

Features:[4]

  • AR +ve.
  • Calretinin -ve.
    • Surrounding stroma +ve.
  • Inhibin +ve.[4]

See also

References

  1. Bilici, A.; Inanc, M.; Ulas, A.; Akman, T.; Seker, M.; Babacan, NA.; Inal, A.; Bal, O. et al. (2013). "Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology.". Asian Pac J Cancer Prev 14 (11): 6493-9. PMID 24377556.
  2. Arnogiannaki, N.; Grigoriadis, C.; Zygouris, D.; Terzakis, E.; Sebastiadou, M.; Tserkezoglou, A. (2011). "Proliferative Brenner tumor of the ovary. clinicopathological study of two cases and review of the literature.". Eur J Gynaecol Oncol 32 (5): 576-8. PMID 22053680.
  3. Ali, RH.; Seidman, JD.; Luk, M.; Kalloger, S.; Gilks, CB. (Nov 2012). "Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.". Int J Gynecol Pathol 31 (6): 499-506. doi:10.1097/PGP.0b013e31824d7445. PMID 23018212.
  4. 4.0 4.1 4.2 Kuhn, E.; Ayhan, A.; Shih, IeM.; Seidman, JD.; Kurman, RJ. (Dec 2013). "Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.". Eur J Cancer 49 (18): 3839-49. doi:10.1016/j.ejca.2013.08.011. PMID 24012099.
  5. Amin MB (February 2005). "Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors". Mod. Pathol. 18 Suppl 2: S131–45. doi:10.1038/modpathol.3800314. PMID 15502808.
  6. 6.0 6.1 Nucci, Marisa R.; Oliva, Esther (2009). Gynecologic Pathology: A Volume in Foundations in Diagnostic Pathology Series (1st ed.). Churchill Livingstone. pp. 437. ISBN 978-0443069208.
  7. Gezginç, K.; Karatayli, R.; Yazici, F.; Acar, A.; Çelik, Ç.; Çapar, M.; Tavli, L. (Aug 2012). "Malignant Brenner tumor of the ovary: analysis of 13 cases.". Int J Clin Oncol 17 (4): 324-9. doi:10.1007/s10147-011-0290-7. PMID 21796330.
  8. 8.0 8.1 Borah, T.; Mahanta, RK.; Bora, BD.; Saikia, S. (Jan 2011). "Brenner tumor of ovary: An incidental finding.". J Midlife Health 2 (1): 40-1. doi:10.4103/0976-7800.83273. PMC 3156501. PMID 21897739. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156501/.
  9. Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders. pp. 1098. ISBN 0-7216-0187-1.
  10. Zhang Y, Staley SA, Tucker K, Clark LH (May 2019). "Malignant Brenner tumor of the ovary: Case series and review of treatment strategies". Gynecol Oncol Rep 28: 29–32. doi:10.1016/j.gore.2019.02.003. PMC 6378317. PMID 30815527. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378317/.